Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2023-12-08 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于公司提供财务资助的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the provision of financial assistance to its subsidiaries and related parties. It includes descriptions of financial support amounts, terms, risk analysis, and opinions from the board and independent directors. The content focuses on financial assistance arrangements, shareholder equity changes due to subsidiary share transfers, and risk control measures. It is not a financial report like an annual or interim report, nor is it a regulatory certification or a simple announcement of a report. It is a regulatory announcement about financing activities related to the company's subsidiaries and capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (7278 characters) and detailed financial data support this classification with high confidence.
2023-12-08 Chinese
独立董事工作制度（2023年12月）
Governance Information Classification · 95% confidence The document is titled "独立董事工作制度" which translates to "Independent Director Work System". It details the governance structure, qualifications, duties, nomination, election, and working conditions of independent directors at Shenzhen Haier Bioengineering Co., Ltd. The content focuses on internal governance rules and procedures related to the board of directors, specifically independent directors. There is no financial data, no mention of annual or quarterly results, no voting results, no legal proceedings, no capital changes, and no earnings information. The document is a governance-related policy or internal rules document. Therefore, it fits best under Governance Information (CGR). The document length is 7232 characters, indicating it is a full policy document, not a brief announcement or certification.
2023-12-08 Chinese
关于修订《公司章程》部分条款的公告
Governance Information Classification · 95% confidence The document is a detailed announcement about amendments to the company's Articles of Association (公司章程), including changes to governance rules, board structure, independent director qualifications, and shareholder meeting procedures. It references compliance with regulatory rules such as those from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The content is focused on governance and internal company rules rather than financial results or audit opinions. It is not a full annual report, audit report, or earnings release. It is also not a simple announcement of a report publication but a substantive governance document. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-12-08 Chinese
独立董事候选人声明与承诺
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate for Shenzhen Haier Bioengineering Co., Ltd. It details the candidate's qualifications, compliance with relevant laws and regulations, and commitments related to the role of an independent director. There are no financial statements, earnings data, or report summaries present. The document is not an announcement of a report publication but a formal declaration related to board/management matters, specifically concerning the nomination and qualifications of a board member. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4237 characters, which is consistent with a detailed declaration rather than a brief announcement or a full report.
2023-12-08 Chinese
第九届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a resolution passed at a supervisory board meeting of Shenzhen Haiwang Bioengineering Co., Ltd. It details the meeting date, attendance, agenda item (approval of a financial assistance proposal), and voting results. It references that the proposal will be submitted to the shareholders' meeting and mentions related announcements published elsewhere. The document is short (582 characters) and serves as a meeting resolution announcement rather than a full report or detailed financial disclosure. It does not contain financial statements, audit information, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-08 Chinese
审计委员会工作细则（2023年12月）
Governance Information Classification · 95% confidence The document is titled as the "Audit Committee Working Rules" of Shenzhen Haier Bioengineering Co., Ltd., revised in December 2023. It details the composition, responsibilities, meeting procedures, and authority of the Audit Committee within the company's board. The content focuses on governance, internal control, audit oversight, and committee operations rather than presenting financial statements or audit results. It is a governance-related document outlining internal rules and procedures for the audit committee, not an audit report or annual report itself. Therefore, it fits best under Governance Information (CGR). The document length (5785 characters) and detailed procedural content support this classification rather than a short announcement or a financial report.
2023-12-08 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.